论文部分内容阅读
目的：制备与鉴定人类天然杀菌及通透性增强蛋白，寻找抗ＬＰＳ新药。方法：自慢性粒细胞性增生患者全血提取人粒细胞杀菌蛋白（ＢＰ）。ＳＤＳＰＥＧＥ电泳测定分子量，水解法测定氨基酸组成，普通细胞菌培养检测对Ｏ１１１Ｂ４大肠杆菌的杀伤作用。体内鉴定采用腹腔脓毒症小鼠模型，与抗内毒素单克隆抗体１Ａ比较。观察指标：血ＬＰＳ使用定量的鲎试剂分析法。血细胞因子活性：ＩＬ１采用小鼠胸腺细胞增值法；ＩＬ６采用小鼠淋巴细胞系７ＴＤ１细胞增值法；ＴＮＦ采用Ｌ９２９细胞溶解法。结果：得到５５ＫＤ蛋白，具有杀菌和中和ＬＰＳ特性。该蛋白体外中和ＬＰＳ的能力强于１Ａ。小鼠脓毒症模型血ＬＰＳ水平：ＢＰ和１Ａ组明显低于ＮＳ组（Ｐ＜０．０５）。血细胞因子活性：ＢＰ组的抑制作用较强，ＩＬ１，ＩＬ６和ＴＮＦ活性均低于ＮＳ组，有显著性差异（Ｐ＜０．０５）；１Ａ只对ＩＬ６有抑制作用（Ｐ＜０．０５）。结论：ＢＰ在阻断ＬＰＳ和抑制炎症反应方面优于抗ＬＰＳ单抗。
OBJECTIVE: To prepare and identify human natural bactericidal and permeability enhancing proteins and to search for new anti-LPS drugs. Methods: Human whole blood bactericidal protein (BP) was extracted from whole blood of patients with chronic myelocytic hyperplasia. SDS PEGE electrophoresis determination of molecular weight, hydrolysis of amino acid composition, the detection of ordinary cell culture on O111B4 Escherichia coli killing effect. In vivo identification using intraperitoneal sepsis mouse model, and anti-endotoxin monoclonal antibody 1A comparison. OUTCOME MEASURES: Blood LPS using quantitative 鲎 reagent analysis. Blood cytokine activity: IL 1 mouse thymocyte proliferation method; IL 6 mouse lymphocyte line 7TD1 cell proliferation method; TNF L929 cell lysis method. Results: 55KD protein was obtained with bactericidal and neutralizing LPS properties. The ability of this protein to neutralize LPS in vitro is stronger than that of 1A. Blood LPS levels in mice sepsis model: BP and 1A group was significantly lower than NS group (P <0.05). Blood cytokines activity: the inhibition of BP group stronger, IL 1, IL 6 and TNF activity were lower than the NS group, a significant difference (P <0.05); 1A only IL 6 inhibition P <0.05). Conclusion: BP is superior to anti-LPS monoclonal antibody in blocking LPS and inhibiting inflammatory response.